Editas (EDIT) Up 9.3% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 12/05/20
Editas Medicine Announces Preclinical Data and Large-Scale Manufacturing Process for EDIT-301, in Development for the Treatment of Sickle Cell Disease and Beta-ThalassemiaGlobeNewsWire • 12/05/20
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/06/20
Editas Medicine to Host Conference Call Discussing Third Quarter 2020 Results and Corporate UpdateGlobeNewsWire • 10/29/20
Editas Medicine Announces U.S. Patent and Trademark Office Grants the Broad Institute Priority Benefit in CRISPR InterferenceGlobeNewsWire • 09/11/20
Editas Medicine Receives Rare Pediatric Disease Designation for EDIT-301 for the Treatment of Sickle Cell DiseaseGlobeNewsWire • 08/24/20
Editas Medicine, Inc. (EDIT) CEO Cindy Collins on Q2 2020 Results - Earnings Call TranscriptSeeking Alpha • 08/07/20
Here's Why Shares of Editas Medicine and Beam Therapeutics Are Soaring TodayThe Motley Fool • 08/06/20
Earnings Preview: Editas Medicine (EDIT) Q2 Earnings Expected to DeclineZacks Investment Research • 07/30/20
Catalent Enters into Strategic Partnership with Editas Medicine to Support Gene Editing Medicine PipelineGlobeNewsWire • 07/29/20